Overview

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Status:
RECRUITING

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Ascentage Pharma Group Inc.

Treatments:

Decitabine
olverembatinib